A class action has been filed against Barrier Therapeutics, Inc. (BTRX), certain of its officers and directors by stockholders who purchased the company's common stock between April 29, 2004 and June 29, 2005. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The stockholders seek to recover compensatory damages for the loss of value of their stock.

According to a press release dated October 11, 2005, the complaint charges Barrier and certain of its officers and directors with violations of the Securities Act of 1933 and Securities Exchange Act of 1934. Barrier is a biopharmaceutical company, engaged in the discovery, development, and commercialization of pharmaceutical products in the field of dermatology. The complaint alleges that Barrier made a series of materially false and misleading statements concerning the Company's business and products under development. In particular, the Complaint alleges that these statements were materially false and misleading because they failed to disclose and misrepresented the following adverse facts: (i) that the Company had failed to perform its clinical trials in conformity with FDA guidelines as they had failed to disclose that they had secretly substituted the petroleum base within Zimycan, the effect of which was to substantially lessen the likelihood that the drug could achieve FDA approval; (ii) that Hyphanox did not have a better safety or efficacy profile than fluconazole/Diflucan and, in fact, as investors ultimately learned, Hyphanox was significantly less effective than fluconazole/Diflucan; and (iii) as a result of the foregoing, defendants lacked any reasonable basis for their positive statements about Barrier.

The complaint further alleges that on or around June 29, 2005, Barrier shocked the market when it announced, among other adverse facts, that the Company's drug trials failed to demonstrate that Hyphanox worked as well as fluconazole. In response to this announcement, the price of Barrier stock plummeted over $6.75 per share - - a decline of over 45% - - to below $8.00 per share on extremely heavy trading volume.

The lawsuit has been filed on behalf of all persons who purchased the common stock of Barrier Therapeutics, Inc. between April 29, 2004, and June 29, 2005, inclusive. Also included are those who purchased Barrier pursuant and/or traceable to the Company's Initial Public Offering ("IPO") on or about April 29, 2004 and/or in its Secondary Offering on or about February 9, 2005.

If you bought Barrier Therapeutics, Inc. securities between April 29, 2004 and June 29, 2005, inclusive, and would like to obtain information about the Barrier Therapeutics, Inc. lawsuit, then you are invited to call (866) 467-1400 to speak with an attorney.